Individualized Therapies Incorporating Novel Agents for Non-Small-Cell Lung Cancer: 2013 ASCO Update

This webcast is jointly sponsored by A. Webb Roberts Center for CME of Baylor Health Care System and CancerNet.

This activity is supported by educational grants from: Genentech BioOncology and Lilly USA, LLC.

Specialty: Hematology/Oncology

Release date: October 24, 2013

Valid through: October 24, 2015

Target Audience:

Program Overview:

These webcasts are intended to improve care of patients with NSCLC by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of molecular profiling and personalized therapies at various stages of clinical development will be given significant focus. This enduring online activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.

This program consists of 2 continuing education activites.

The Role of Angiogenesis and MET Inhibition in the Management of Advanced NSCLC — 0.75 AMA PRA Category 1™ Credit Hours

EGFR and Beyond — 0.5 AMA PRA Category 1™ Credit Hours